Comparative toxicity of preservatives on immortalized corneal and conjunctival epithelial cells.
about
Cytotoxicity of five fluoroquinolone and two nonsteroidal anti-inflammatory benzalkonium chloride-free ophthalmic solutions in four corneoconjunctival cell linesHigh molecular weight hyaluronan decreases oxidative DNA damage induced by EDTA in human corneal epithelial cells.Evaluation of biomarkers of inflammation in response to benzalkonium chloride on corneal and conjunctival epithelial cells.Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost.Efficacy, safety, and tolerability of travoprost 0.004% BAK-free versus prior treatment with latanoprost 0.005% in Japanese patientsDetermining the Depth of Injury in Bioengineered Tissue Models of Cornea and Conjunctiva for the Prediction of All Three Ocular GHS Categories.Multiple endpoint analysis of BAC-preserved and unpreserved antiallergic eye drops on a 3D-reconstituted corneal epithelial model.Comparison of hyaluronic acid-containing topical eye drops with carbomer-based topical ocular gel as a tear replacement in canine keratoconjunctivitis sicca: A prospective study in twenty five dogs.Effect of long-term treatment with eyedrops for glaucoma on conjunctival bacterial floraThe Toxicity of Nonsteroidal Anti-inflammatory Eye Drops against Human Corneal Epithelial Cells in Vitro.Comparison of the Efficacy of Fluorometholone With and Without Benzalkonium Chloride in Ocular Surface Disease.Efficacy and tolerability of a gatifloxacin/prednisolone acetate fixed combination for topical prophylaxis and control of inflammation in phacoemulsification: a 20-day-double-blind comparison to its individual components.Ocular preservatives: associated risks and newer options.Ocular toxicity of benzalkonium chloride homologs compared with their mixtures.Benzalkonium chloride and glaucoma.Ophthalmic preservatives: focus on polyquaternium-1.Comparative cross-sectional analysis of the effects of topical antiglaucoma drugs on the ocular surface.Topical delivery of ocular therapeutics: carrier systems and physical methods.N-hydroxymethylglycinate with EDTA is an efficient eye drop preservative with very low toxicity: an in vitro comparative study.Ocular surface toxicity from glaucoma topical medications and associated preservatives such as benzalkonium chloride (BAK).Mechanisms of benzalkonium chloride toxicity in a human trabecular meshwork cell line and the protective role of preservative-free tafluprost.Trehalose-based eye drops preserve viability and functionality of cultured human corneal epithelial cells during desiccation.Impact of topical bimatoprost 0.01% and bimatoprost 0.03% on conjunctival irritation in rabbits.Comparative assessment of the cytotoxicity of six anti-inflammatory eyedrops in four cultured ocular surface cell lines, as determined by cell viability scores.Safety of Cultivated Limbal Epithelial Stem Cell Transplantation for Human Corneal Regeneration.The cytotoxic effects of preserved and preservative-free prostaglandin analogs on human corneal and conjunctival epithelium in vitro and the distribution of benzalkonium chloride homologs in ocular surface tissues in vivo.Patient adherence and persistence with topical ocular hypotensive therapy in real-world practice: a comparison of bimatoprost 0.01% and travoprost Z 0.004% ophthalmic solutions.Ocular inflammation and corneal permeability alteration by benzalkonium chloride in rats: a protective effect of a myosin light chain kinase inhibitor.Implications for Ophthalmic Formulations: Ocular Buffers Show Varied Cytotoxic Impact on Human Corneal-Limbal and Human Conjunctival Epithelial Cells.A Rare Case Report of Conjunctival Cyst.Clinical effect of four different ointment bases on healthy cat eyes.Aqueous humor penetration of topical bimatoprost 0.01% and bimatoprost 0.03% in rabbits.[Preservative-free glaucoma treatment : Selection of the correct treatment in 1 min].Preparation and in vitro/in vivo evaluation of antimicrobial ocular in situ gels containing a disappearing preservative for topical treatment of bacterial conjunctivitis.Balancing antimicrobial efficacy and toxicity of currently available topical ophthalmic preservatives.A patient with corneal epithelial disorder that developed after administration of a latanoprost generic, but not a brand-name drug, eye dropEffects of timolol-related ophthalmic solutions on cultured human conjunctival cells.Effects of benzalkonium chloride- or polyquad-preserved fixed combination glaucoma medications on human trabecular meshwork cells.In vitro effects of preserved and unpreserved anti-allergic drugs on human corneal epithelial cells.Development of a non-settling gel formulation of 0.5% loteprednol etabonate for anti-inflammatory use as an ophthalmic drop.
P2860
Q34161106-9A43E210-A3FD-45D7-BA06-5982BF20A338Q34272980-1101E304-DCA2-403F-A16D-074A82D1E47DQ34309959-B89DAC03-310B-4D22-995A-6272C572BB71Q34357225-AFB665D0-B0CF-4C32-8DA2-A6CE90DA22C9Q34393007-931793E5-B921-41B5-9C30-7E81B11DEF9BQ34672610-D7533F9B-E0FD-4682-B4CB-D207F3CA7DA9Q34708156-EBA76552-7445-4B59-AE44-3F066F83563AQ35035413-B55496D1-4370-409B-84E0-9F04A11376DCQ35547744-3E03BAAE-B99E-4E2D-8B5F-719875898B49Q36400580-7ABBCAB2-13F7-4C16-860F-38F92C12D6C5Q36443965-967053DD-91BB-4638-BC32-2480C7A8018FQ36906812-E6CC491A-BDB1-4EA4-A44F-7AD89CB5B050Q37510923-C02F8663-4F5C-4845-A5EE-A98703893869Q37579359-9C08A486-FA9D-4C4C-A89B-6F3A9D71D6BFQ37710684-03FCDD80-C39D-4984-A1B0-B913240A92E6Q37929746-68D73E95-0F0B-44A7-8B32-634BA9D93971Q38096951-AA6A256E-F095-4C42-879C-20839377D40EQ38196446-61134DAB-D129-41D5-9C56-C1DF3B6B46DAQ38698730-13DFF75A-9B97-4F6C-AF53-58020B413E1EQ38843414-51DCBED8-B7CA-4B03-9F4B-5B40641016E5Q38973872-1404DCBF-D079-4B3A-BED9-9DC6551181F0Q38978082-5D6D84E4-F14D-4569-A286-B9B1B4DCA103Q39221538-60EB09BB-2099-4F95-B7EA-3EDCC1D643C2Q39237556-7BAA1692-CB50-443D-A0A4-BC9A8F3126D5Q39279363-68358C3D-8825-4F65-901E-6F01A33624D8Q39448716-62E823D9-89B8-4E58-AEBE-C1F6C0250FEDQ39791012-678C22BB-D68B-448B-9C61-BE533BD4DCAEQ39990324-14C4CD1F-1102-4BBD-B8B0-6E2C1574EE4CQ40256005-718C2941-0B0F-456A-AAFE-A8C3F3863404Q40868459-8A69DFF4-0251-4F21-8DAE-C44DA76D63BEQ40938734-CD597F66-4EF4-460E-82C0-751D27BB6E31Q41125727-CC676042-2575-4937-8C81-E8CFB09F04F9Q41127717-49C3E81F-5179-4DED-87DB-5BFD7C0C1D26Q41321186-B2F34EB0-C77D-4D96-AF8E-A45CD7D13080Q41717624-5428BDD4-1CB2-4A66-8876-FEEB31011B77Q42237372-7C4C03A4-299C-40EE-8836-6C2D9B96754FQ42769999-724D35BF-80A9-4F10-BA64-955F7F542549Q42794581-F3E9B27B-40D7-4E83-865D-8DC5F1C3C401Q42975877-06DC004C-A6C4-4805-AD8C-E0E6FA39C5A7Q43245437-3754B916-9663-4049-812C-A1A32C91A5F1
P2860
Comparative toxicity of preservatives on immortalized corneal and conjunctival epithelial cells.
description
2009 nî lūn-bûn
@nan
2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Comparative toxicity of preser ...... conjunctival epithelial cells.
@ast
Comparative toxicity of preser ...... conjunctival epithelial cells.
@en
Comparative toxicity of preser ...... conjunctival epithelial cells.
@nl
type
label
Comparative toxicity of preser ...... conjunctival epithelial cells.
@ast
Comparative toxicity of preser ...... conjunctival epithelial cells.
@en
Comparative toxicity of preser ...... conjunctival epithelial cells.
@nl
prefLabel
Comparative toxicity of preser ...... conjunctival epithelial cells.
@ast
Comparative toxicity of preser ...... conjunctival epithelial cells.
@en
Comparative toxicity of preser ...... conjunctival epithelial cells.
@nl
P2093
P2860
P356
P1476
Comparative toxicity of preser ...... conjunctival epithelial cells.
@en
P2093
Edward Marcus
Michael Ahdoot
Seth P Epstein
P2860
P304
P356
10.1089/JOP.2008.0098
P50
P577
2009-04-01T00:00:00Z